{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:07Z","timestamp":1791972727690,"version":"4.3.4"},"reference-count":112,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272695"],"award-info":[{"award-number":["82272695"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LZ23H160004"],"award-info":[{"award-number":["LZ23H160004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bbcan.2024.189108","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T02:03:09Z","timestamp":1715133789000},"page":"189108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer"],"prefix":"10.1016","volume":"1879","author":[{"given":"Wei","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10299","key":"10.1016\/j.bbcan.2024.189108_bb0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.bbcan.2024.189108_bb0010","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1039\/D2TB02277J","article-title":"Recent progress of biosensors for the detection of lung cancer markers","volume":"11","author":"Chen","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2024.189108_bb0020","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.21037\/tlcr.2018.03.19","article-title":"Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer","volume":"7","author":"Gregorc","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"issue":"suppl_1","key":"10.1016\/j.bbcan.2024.189108_bb0025","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189108_bb0035","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung Cancer and acquired resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2024.189108_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23136936","article-title":"Acquired resistance to Osimertinib in EGFR-mutated non-small cell lung Cancer: how do we overcome it?","volume":"23","author":"Bertoli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189108_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189108_bb0050","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bbcan.2024.189108_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung Cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2024.189108_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpg.2023.101839","article-title":"Colorectal cancer: a health and economic problem","volume":"66","author":"Klimeck","year":"2023","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.trecan.2022.10.001","article-title":"Precision oncology provides opportunities for targeting KRAS-inhibitor resistance","volume":"9","author":"Sattler","year":"2023","journal-title":"Trends Cancer."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100745","article-title":"Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era","volume":"8","author":"Ciardiello","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.bbcan.2024.189108_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104228","article-title":"KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)","volume":"195","author":"Rosell","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189108_bb0090","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","article-title":"The KRAS-G12C inhibitor: activity and resistance","volume":"29","author":"Liu","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189108_bb0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189108_bb0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0092-8674(00)00115-X","article-title":"Ras and rho GTPases: a family Reunion","volume":"103","author":"Bar-Sagi","year":"2000","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","article-title":"Emerging strategies to target RAS signaling in human cancer therapy","volume":"14","author":"Chen","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189108_bb0110","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1073\/pnas.79.11.3637","article-title":"Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses","volume":"79","author":"Der","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0115","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189108_bb0120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7782","key":"10.1016\/j.bbcan.2024.189108_bb0125","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/d41586-019-03242-8","article-title":"Small molecule combats cancer-causing KRAS protein at last","volume":"575","author":"Herbst","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","article-title":"Drugging KRAS: current perspectives and state-of-art review","volume":"15","author":"Parikh","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2024.189108_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.890247","article-title":"Light at the end of the tunnel: clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbcan.2024.189108_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189108_bb0145","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common Cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189108_bb0150","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.21037\/tlcr-20-455","article-title":"KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples","volume":"9","author":"Loong","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"22","key":"10.1016\/j.bbcan.2024.189108_bb0155","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189108_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/2632010X221102054","article-title":"Molecular signatures of KRAS-mutated lung adenocarcinoma: analysis of concomitant EGFR, ALK, STK11, and PD-L1 status","volume":"15","author":"Hsu","year":"2022","journal-title":"Clin. Pathol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0165","article-title":"The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)","volume":"2","author":"Salgia","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189108_bb0170","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung Cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189108_bb0175","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"14","key":"10.1016\/j.bbcan.2024.189108_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143579","article-title":"KRAS G12C mutation in metastatic colorectal cancer: prognostic implications and advancements in targeted therapies","volume":"vol. 15","author":"Ottaiano","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","article-title":"MEK inhibitors for the treatment of non-small cell lung cancer","volume":"14","author":"Han","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189108_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020709","article-title":"KRAS mutations in solid tumors: characteristics, current therapeutic strategy, and potential treatment exploration","volume":"12","author":"Yang","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0195","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"issue":"19","key":"10.1016\/j.bbcan.2024.189108_bb0200","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1016\/j.molcel.2021.07.021","article-title":"A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies","volume":"81","author":"Liu","year":"2021","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189108_bb0205","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.biochi.2008.10.010","article-title":"p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling","volume":"91","author":"Pamonsinlapatham","year":"2009","journal-title":"Biochimie"},{"issue":"446","key":"10.1016\/j.bbcan.2024.189108_bb0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao2565","article-title":"The ERBB network facilitates KRAS-driven lung tumorigenesis","volume":"10","author":"Kruspig","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"13","key":"10.1016\/j.bbcan.2024.189108_bb0215","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/hmg\/ddy133","article-title":"Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth","volume":"27","author":"Tajan","year":"2018","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0220","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13041-019-0517-5","article-title":"The impact of RASopathy-associated mutations on CNS development in mice and humans","volume":"12","author":"Kang","year":"2019","journal-title":"Mol. Brain"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189108_bb0225","doi-asserted-by":"crossref","first-page":"R319","DOI":"10.1530\/ERC-19-0098","article-title":"Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer","volume":"26","author":"Zaballos","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2024.189108_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111562","article-title":"Immune checkpoint inhibitors and RAS-ERK pathway-targeted drugs as combined therapy for the treatment of melanoma","volume":"12","author":"Morante","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbcan.2024.189108_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(09)02001-6","article-title":"Ras signaling and therapies","volume":"102","author":"Young","year":"2009","journal-title":"Adv. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189108_bb0240","doi-asserted-by":"crossref","first-page":"381","DOI":"10.21037\/atm-22-403","article-title":"An advanced non-small cell lung cancer patient with EGFR and KRAS mutations, and PD-L1 positive, benefited from immunotherapy: a case report","volume":"10","author":"Yang","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189108_bb0245","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189108_bb0250","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/21541248.2016.1262935","article-title":"Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-a connection to licensing nodes","volume":"9","author":"Schneeweis","year":"2018","journal-title":"Small GTPases."},{"issue":"13","key":"10.1016\/j.bbcan.2024.189108_bb0255","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.7150\/thno.71260","article-title":"Conquering oncogenic KRAS and its bypass mechanisms","volume":"12","author":"Hou","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2024.189108_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.931774","article-title":"Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation","volume":"12","author":"Avery","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2024.189108_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189108_bb0270","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/0008-5472.CAN-16-0357","article-title":"Gastric Cancer cell proliferation and survival is enabled by a Cyclophilin B\/STAT3\/miR-520d-5p signaling feedback loop","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189108_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030398","article-title":"KRAS as a modulator of the inflammatory tumor microenvironment: therapeutic implications","volume":"11","author":"Pereira","year":"2022","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.bbcan.2024.189108_bb0280","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1158\/1078-0432.CCR-22-3655","article-title":"Facts and hopes on RAS inhibitors and Cancer immunotherapy","volume":"29","author":"Boumelha","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189108_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071785","article-title":"Cell type-specific roles of STAT3 signaling in the pathogenesis and progression of K-ras mutant lung adenocarcinoma","volume":"14","author":"Clowers","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0290","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s13046-019-1405-7","article-title":"The JAK2\/STAT3\/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance","volume":"38","author":"Park","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189108_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020603","article-title":"The multifaced role of STAT3 in Cancer and its implication for anticancer therapy","volume":"22","author":"Tolomeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189108_bb0300","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153470","article-title":"Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47","volume":"133","author":"Hu","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12964-023-01063-x","article-title":"Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions","volume":"21","author":"Watterson","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"7607","key":"10.1016\/j.bbcan.2024.189108_bb0310","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2024.189108_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101780","article-title":"Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling","volume":"38","author":"Glorieux","year":"2021","journal-title":"Redox Biol."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189108_bb0320","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"35","key":"10.1016\/j.bbcan.2024.189108_bb0325","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.1901765116","article-title":"ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer","volume":"116","author":"Hashimoto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0330","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"25","key":"10.1016\/j.bbcan.2024.189108_bb0335","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0340","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-021-01422-7","article-title":"Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer"},{"issue":"18","key":"10.1016\/j.bbcan.2024.189108_bb0345","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-term outcomes and molecular correlates of Sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung Cancer: 2-year analysis of CodeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10378","key":"10.1016\/j.bbcan.2024.189108_bb0350","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189108_bb0355","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/0929867330666230330122000","article-title":"First approval of Adagrasib for the treatment of non-small cell lung Cancer harboring a KRAS(G12C) mutation","volume":"31","author":"De","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189108_bb0360","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung Cancer harboring a KRAS(G12C) mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0365","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189108_bb0370","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, Sotorasib and Adagrasib, and overcoming strategies: insights from in vitro experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2024.189108_bb0375","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/OTT.S340392","article-title":"Targeting KRAS (G12C)-mutated advanced colorectal Cancer: research and clinical developments","volume":"15","author":"Ji","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0380","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","article-title":"Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal Cancer","volume":"13","author":"Yaeger","year":"2023","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189108_bb0385","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189108_bb0390","doi-asserted-by":"crossref","first-page":"181","DOI":"10.21037\/tlcr-23-47","article-title":"Understanding KRAS for better targeting","volume":"12","author":"Patel","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0395","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in colorectal Cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bbcan.2024.189108_bb0400","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in refractory colorectal Cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189108_bb0405","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1007\/s12094-022-02877-w","article-title":"Colorectal cancer-derived exosomes and modulation KRAS signaling","volume":"24","author":"Wan","year":"2022","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188677","article-title":"Reflections on drug resistance to KRAS(G12C) inhibitors and gene silencing\/editing tools for targeting mutant KRAS in cancer treatment","volume":"1877","author":"Han","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2024.189108_bb0415","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"issue":"25","key":"10.1016\/j.bbcan.2024.189108_bb0420","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189108_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103524","article-title":"KRAS-G12C covalent inhibitors: a game changer in the scene of cancer therapies","volume":"168","author":"Naim","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"18","key":"10.1016\/j.bbcan.2024.189108_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184467","article-title":"Inhibition of KRAS, MEK and PI3K demonstrate synergistic anti-tumor effects in pancreatic ductal adenocarcinoma cell lines","volume":"14","author":"Ma","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.bbcan.2024.189108_bb0435","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-21-0856","article-title":"KRAS inhibitor resistance in MET-amplified KRAS (G12C) non-small cell lung Cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms","volume":"27","author":"Suzuki","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0440","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189108_bb0445","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2024.189108_bb0450","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2020.09.004","article-title":"KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma","volume":"149","author":"Gao","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2024.189108_bb0455","doi-asserted-by":"crossref","first-page":"1004669","DOI":"10.3389\/fonc.2022.1004669","article-title":"Non-genetic adaptive resistance to KRAS(G12C) inhibition: EMT is not the only culprit","volume":"12","author":"Ning","year":"2022","journal-title":"Front. Oncol."},{"issue":"Pt 7","key":"10.1016\/j.bbcan.2024.189108_bb0460","first-page":"1523","article-title":"Tead2 expression levels control the subcellular distribution of yap and Taz, zyxin expression and epithelial-mesenchymal transition","volume":"127","author":"Diepenbruck","year":"2014","journal-title":"J. Cell Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189108_bb0465","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00018-020-03579-8","article-title":"An overview of signaling pathways regulating YAP\/TAZ activity","volume":"78","author":"Heng","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189108_bb0470","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.12039","article-title":"Combined targeting of MEK\/MAPK and PI3K\/Akt signalling in multiple myeloma","volume":"159","author":"Steinbrunn","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"6662","key":"10.1016\/j.bbcan.2024.189108_bb0475","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn4180","article-title":"Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors","volume":"381","author":"Lv","year":"2023","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.bbcan.2024.189108_bb0480","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169391","article-title":"KRAS-mutant non-small-cell lung Cancer: from past efforts to future challenges","volume":"23","author":"Ceddia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2024.189108_bb0485","doi-asserted-by":"crossref","first-page":"1090838","DOI":"10.3389\/fimmu.2023.1090838","article-title":"Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"29","key":"10.1016\/j.bbcan.2024.189108_bb0490","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8780","article-title":"Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers","volume":"8","author":"Mugarza","year":"2022","journal-title":"Sci. Adv."},{"issue":"7781","key":"10.1016\/j.bbcan.2024.189108_bb0495","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bbcan.2024.189108_bb0500","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal Cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189108_bb0505","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","article-title":"The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy","volume":"20","author":"Briere","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0510","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.5280","article-title":"MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells","volume":"249","author":"Stutvoet","year":"2019","journal-title":"J. Pathol."},{"issue":"21","key":"10.1016\/j.bbcan.2024.189108_bb0515","doi-asserted-by":"crossref","first-page":"14614","DOI":"10.1021\/acs.jmedchem.2c01120","article-title":"Fragment optimization of reversible binding to the switch II pocket on KRAS leads to a potent, in vivo active KRAS(G12C) inhibitor","volume":"65","author":"Broker","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2024.189108_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108050","article-title":"Resistance looms for KRAS G12C inhibitors and rational tackling strategies","volume":"229","author":"Zhang","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189108_bb0525","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nsmb.1591","article-title":"Converging concepts of protein folding in vitro and in vivo","volume":"16","author":"Hartl","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0530","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/acsmedchemlett.9b00584","article-title":"PROTAC-mediated degradation of KRAS protein for anticancer therapeutics","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189108_bb0535","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189108_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28083615","article-title":"Multiple strategies to develop small molecular KRAS directly bound inhibitors","volume":"28","author":"Zhou","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189108_bb0545","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"issue":"45","key":"10.1016\/j.bbcan.2024.189108_bb0550","doi-asserted-by":"crossref","first-page":"16314","DOI":"10.1002\/anie.201910124","article-title":"Bifunctional small-molecule ligands of K-Ras induce its association with Immunophilin proteins","volume":"58","author":"Zhang","year":"2019","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"6659","key":"10.1016\/j.bbcan.2024.189108_bb0555","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189108_bb0560","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.7150\/thno.17841","article-title":"SiRNA delivery with PEGylated graphene oxide Nanosheets for combined Photothermal and Genetherapy for pancreatic Cancer","volume":"7","author":"Yin","year":"2017","journal-title":"Theranostics"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T03:08:00Z","timestamp":1720667280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X24000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0304419X24000398"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189108","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"189108"}}